Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 aldoxorubicin versus investigator's choice in relapsed or refractory advanced soft tissue sarcoma
2013-004103-40Phase 3Completed
- Sponsor
- LadRx
- Start
- Feb 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldoxorubicin in soft tissue sarcoma (STS) (2 arms), sponsored by LadRx. Primary endpoint: Progression-free survival. Started Feb 2014; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2013-004103-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004103-40.